Postprandial metabolic heterogeneity in men with primary dyslipidaemia by Pavlidis, Antonios N. et al.
Postprandial metabolic heterogeneity in men with
primary dyslipidaemia
Antonios N. Pavlidis
1, Genovefa D. Kolovou
1, Katherine K. Anagnostopoulou
2, Petros C. Petrou
1, 
Dennis V. Cokkinos
1
Abstract
Introduction:  Familial combined hyperlipidaemia (FCH) and familial
hypercholesterolaemia (FH) have been strongly linked to premature coronary
artery disease. Postprandial hypertriglyceridaemia is also associated with
atherosclerotic disease. We evaluated the postprandial lipaemia in men with
FCH and FH and compared them to a group of healthy men.
Material and methods: The study population consisted of 83 men: 34 FCH, 29 FH
and 20 healthy. The FCH and FH groups were further divided into five subgroups,
according to their lipid phenotype: FCH-IIA (n = 13), FCH-IIB (n = 10), FCH-IV 
(n = 11), FH-IIA (n = 21) and FH-IIB (n = 8). Postprandial lipaemia was evaluated
by the areas under the curve for triglyceride (TG) concentrations (TG-AUC).
Results: The TG levels after oral fat tolerance test were significantly higher in
FCH, compared to FH and healthy groups (TG-AUC in mg/dl/h; 2678 ±1415 vs.
1503 ±1147 and 1011 ±652 respectively, p < 0.001). The postprandial response
was higher in FCH-IV and FCH-IIB, compared to FCH-IIA (TG-AUC in mg/dl/h;
3220 ±824 or 3409 ±770 vs. 1863 ±577 respectively, p < 0.001, for both
comparisons). The FCH-IIA group showed higher postprandial TG levels when
compared to FH-IIA (TG-AUC in mg/dl/h; 1863 ±577 vs. 1374 ±428 respectively,
p = 0.008). There were no significant differences between FH-IIB and FCH-IIB
subgroups. There was a significant correlation (r = 0.907, p < 0.001) between
the postprandial TG-AUC and fasting TG levels in all FCH subjects.
Conclusions: All phenotypes of FCH and the FH IIB phenotype demonstrate an
exaggerated postprandial response that could partially contribute to the high
cardiovascular risk. These patients should be identified and treated early with
the appropriate hypolipidaemic agents.
Key words: postprandial lipaemia, familial combined hyperlipidaemia, familial
hypercholesterolaemia
Introduction
The majority of epidemiological studies (Framingham, Prospective
Cardiovascular Münster [PROCAM], Multiple Risk Factor Intervention 
Trial [MRFIT]) come to conclusions regarding triglycerides (TG) as
a cardiovascular (CV) risk factor, based on fasting TG levels [1-3]. Lately,
studies have suggested that non-fasting TG may predict CV events similarly
or even better, compared to fasting TG, and have the practical advantage
that patients do not need to fast [4]. Also, it is accepted that atherosclerosis
is a postprandial phenomenon; thus investigating the fate of lipoproteins
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after the administration of a fat meal may be very
useful in certain subjects [5, 6]. 
Familial combined hyperlipidaemia (FCH)
accounts for approximately 100,000 myocardial
infarctions per year in the United States and the
European Union [7]. FCH is characterised by intra-
individual and intrafamilial variability of the lipid
profile, expressed as periodic increase of TG and/or
total cholesterol (TC) levels [8]. 
Familial hypercholesterolaemia (FH) is an
autosomal, co-dominant, monogenic disorder of
lipoprotein metabolism, characterised by very high
levels of low density lipoprotein (LDL), tendon
xanthomas and increased risk of premature
atherosclerosis. 
Postprandial lipaemia is a physiological polygenic
metabolic process, following ingestion of dietary
fat, mainly characterised by a marked increase in
TG rich lipoprotein levels, such as chylomicrons
(CM), very low density lipoproteins (VLDL) and their
remnants [5]. 
We evaluated the postprandial TG response after
a fat tolerance meal in men with FCH and FH and
a group of healthy subjects. 
Material and methods
Participants 
The independent ethics committee of the
Onassis Cardiac Surgery Center in Athens approved
the study protocol and all participants gave
informed written consent. The study population
consisted of 83 Greek men who where referred to
our Lipid Clinic. Only patients without hypolipi  -
daemic treatment were eligible to enter the study.
Heavy drinking (more than 3 units/day), thyroid,
liver or renal disorders and professional sport
activity were exclusion criteria. 
This study complies with the Declaration of
Helsinki.
Study groups
The study population was divided into three
main groups:
1. The FH group (n = 29), median age 34 (16). The
diagnosis of FH was based on the widely
accepted Simon Broome diagnostic criteria [9]:
a) TC > 290 mg/dl, LDL cholesterol > 190 mg/dl,
b) tendinous xanthomata in the patient or a first
degree relative, c) family history of myocardial
infarction in a first degree relative age < 60 years
or in a second degree relative age < 50 years and
d) family history of raised TC > 290 mg/dl in a first
or second degree relative.
2. The FCH group (n = 34), median age 47 (14). The
FCH status was diagnosed according to widely used
diagnostic criteria [10, 11]: a) TC and/or TG levels 
> 90th percentile, adjusted for age and gender, on
the basis of the PROCAM study [2], b) primary
variability of the lipid phenotype in the patient
and/or one member of the family, c) plasma apoB
concentrations > 120 mg/dl, d) family history of
myocardial infarction in a first degree relative age
< 60 years, or in a second degree relative 
age < 50 years and e) absence of xanthomas.
3. The control group (n = 20), median age 46 (11).
There was no previous medical history or family
history of premature atherosclerosis, diabetes
mellitus (DM), hypertension or dyslipidaemia.
None of them was receiving any treatment. Three
of the subjects were smokers.
Study subgroups
FCH and FH groups were further divided into
subgroups, according to the Fredrickson lipid
phenotype, by using the Lipid Research Clinic
reference values [12]. Type IIA (hypercholes  -
terolaemic phenotype) defined as TC ≥ 95th
percentile, type IIB (mixed, hypercholesterolaemic
and hypertriglyceridaemic phenotype) as both TG
and TC ≥ 90th percentile and type IV
(hypertriglyceridaemic phenotype) as TG ≥ 95th
percentile. 
FH subjects were divided into two subgroups,
FH-IIA (n = 21) and FH-IIB (n = 8), and FCH subjects
into three subgroups, FCH-IIA (n = 13), FCH-IIB 
(n = 10) and FCH-IV (n = 11). Postprandial TG
response was compared among the three different
FCH subgroups, as well as between FH and FCH
subgroups with the same lipid phenotype (FH-IIA
vs. FCH-IIA and FH-IIB vs. FCH-IIB).
Fat tolerance test 
All subjects underwent a standardized oral fat
tolerance test (FTT) following a 12 h overnight fast.
Participants were forbidden to eat for 8 h after
consumption of the meal, but were allowed free
access to water. Each participant was given a meal
containing 75 g fat/m2 of body surface area, as
previously described [13]. The meal provided 83.5%
of energy from fat, 14.0% from carbohydrates and
2.5% from protein and was given in a dose based
on the patient’s body surface area (350 g for 2 m2).
It was consumed within 20 minutes and TG levels
were measured at 0, 2, 4, 6 and 8 hours (h). TC and
high density lipoprotein (HDL) levels were only
measured in the fasting state, since it is has been
shown that their levels do not present significant
alterations postprandially [14, 15]. 
Plasma lipid, lipoprotein and apolipoprotein
analysis
Plasma TC, TG and HDL cholesterol levels were
measured using enzymatic colorimetric methods,Arch Med Sci 6, December / 2010 881
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on a Roche Integra Biochemical analyser, with
commercially available kits (Roche Diagnostics
GmbH, Mannheim, Germany). The serum LDL
cholesterol levels were calculated using the
Friedewald formula [16], only in subjects with TG
levels < 400 mg/dl. Three FCH patients had TG 
> 400 mg/dl, so LDL was not calculated. ApoA, apoB
and Lp(a) were measured by nephelometry
(Nephelometer: BN-100, Behring, Germany). All
samples were analysed within 24 h.
Glucose, insulin and insulin resistance analysis
Blood glucose was measured by the hexokinase
method with a Dade Behring reagent on
a Dimension (Dade Behring, Liederbach, Germany)
instrument and blood insulin with the IMX ABBOTT
Diagnostics instrument. Whole-body insulin
resistance was assessed with the HOMA-IR formula
(fast glucose × fast insulin/22.5) [17]. All samples
were analysed within 24 h.
Statistical methods
All data were collected in an MS-Excel 2007
spreadsheet and analysed using SPSS 14.0 (SPSS
Inc, Chicago, Illinois, USA) for Windows. Categorical
variables are presented as percentages. Values of
numerical characteristics were tested for normality
and are presented as mean value (± SD) if normally
distributed, and median (± IQR) if not distributed
normally. Area under the curve (AUC) for serial
measurements of TG levels at baseline and after
the fatty meal was calculated using the trapezoid
rule. An ANOVA or Kruskal-Wallis H test with
a Bonferroni correction (whichever appropriate) was
performed for three group comparisons. The t-test
for independent samples or the Mann-Whitney
U test was used for the comparison of numerical
values between different groups, where appropriate.
Chi square test was performed for comparison of
categorical values between groups. Spearman’s rank
correlation coefficient was used as a measure of
association between variables in order to reveal any
correlation between values not normally distributed.
The level of significance was set at p ≤ 0.05.
Results
The fat loading test was ingested and tolerated
well by all subjects. The amount of fatty meal
ingested was 341 (19) g, 341 (35) g and 357 (41) g
for controls, FH and FCH groups respectively.
Baseline characteristics of the three main
groups
Clinical characteristics of the three main groups
(controls, FH and FCH) are shown in Table I.
FCH subjects had higher body mass index (BMI)
and waist values, compared to controls and FH. As
expected, DM, insulin resistance and hypertension
were also more prevalent in the FCH group,
compared to others. Fasting TG (TG0) levels were
significantly higher in the FCH group, compared to
controls and FH, and were also higher in FH
compared to controls.
Baseline characteristics of different subgroups
Clinical characteristics of the five subgroups 
(FH-IIA, FH-IIB, FCH-IIA, FCH-IIB, and FCH-IV) are
summarised in Table II.
The FCH-IIA group had higher BMI and waist
values, compared to FH-IIA. DM and hypertension
were more prevalent in FCH-IIA, compared to 
FH-IIA. FCH-IIB and FCH-IV had higher TG0 levels
compared to FCH-IIA (p < 0.001). Metabolic
syndrome was more prevalent in FCH-IV, compared
to FCH-IIB (p = 0.04), as well as in FCH-IIA,
compared to FH-IIA (p = 0.001). No differences were
observed in TG0 levels between FH and FCH
subgroups with the same Fredrickson phenotype.
Postprandial characteristics of the three main
groups
FCH showed significantly increased postprandial
TG levels, at all hours, compared to controls and
FH. FH showed significantly increased postprandial
TG levels, at all hours, compared to controls. 
Postprandial characteristics of different
subgroups
Comparison of postprandial TG levels between
the three different FCH subgroups is shown in
Figure 1. 
FCH-IV and FCH-IIB showed higher area under
the curve for TG concentrations (TG-AUC),
compared to FCH-IIA (p < 0.001). TG-AUC in FCH-IIA
was significantly higher, compared to FH-IIA 
(p = 0.008). No significant postprandial differences
were observed between FCH-IV and FCH-IIB or
between FH-IIB and FCH-IIB subgroups.
Correlations
There was a significant correlation (r = 0.907, 
p < 0.001) between the postprandial TG-AUC values
and TG0 in all FCH subjects. There were no
significant correlations in the control group.
A correlation between fasting TG levels and
postprandial lipaemia in men with FH has already
been shown [18].
Discussion
We evaluated the response to FTT in the two
most common hereditary dyslipidaemias and882 Arch Med Sci 6, December / 2010
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a group of healthy subjects. We showed that FCH
subjects demonstrate significant postprandial
hypertriglyceridaemia, compared to FH and healthy
subjects. In addition, FCH subjects with hyper  -
triglyceridaemic (IV) and mixed (IIB) phenotypes
show an exaggerated response to a fatty meal,
compared to FCH subjects with hyperchole  -
sterolaemic (IIA) phenotype. On the other hand,
postprandial lipaemia is more pronounced in
hypercholesterolaemic FCH, compared to hyper  -
cholesterolaemic FH.
The prevalence of metabolic syndrome (defined
by ATPIII) [14] among FCH subjects was 68%, which
is similar to that reported by others [19]. In line with
previous studies, postprandial hypertriglyceridaemia
was more significant in FH patients, compared to
healthy subjects [18] and TG0 levels were positively
correlated to the amount of postprandial lipaemia,
as expressed by TG-AUC [15, 18, 20-22]. We
previously showed that FH patients with an
abnormal TG response had higher baseline TG
levels, compared to FH with a normal response [18].
Therefore, in the current study we did not assess
the differences in the postprandial response
between FH patients with hypercholesterolaemic
and mixed phenotypes. Conflicting opinions exist
regarding the role of LDL receptors (LDLr) in
chylomicron clearance in FH patients [23-25].
Nevertheless, delayed chylomicron clearance,
secondary to LDLr deficiency, is considered as one
of the possible mechanisms responsible for the
abnormal postprandial response in some FH
subjects [26]. Moreover, coexistence of mutations
in the LDLr related protein (LRP) has been linked to
LDLr mRNA downregulation, in the postprandial
state [27].
An abnormal response to fat loading in FCH
patients has already been demonstrated by other
Characteristics Controls (n = 20) FH (n = 29) FCH (n = 34) p values
Age [years] 46 (11) 34 (16) 47 (14) A: < 0.001; B: NS; C: 0.001
Body mass index  [kg/m2] 26 (3) 25 (4) 28 (4) A: NS; B: 0.002; C: < 0.001
Waist [cm] 94 (10) 95 (12) 103 (12) A: NS; B: 0.007; C: 0.001
Coronary heart disease  –/+ 20/0 25/4 27/7 A: 0.035; B: 0.008; C: NS
Hypertension  –/+ 20/0 25/4 21/13 A: 0.035; B: < 0.001; C: 0.026
Smokers  –/+ 17/3 16/13 11/23 A: 0.024; B: < 0.001; C: NS
Diabetes mellitus  –/+ 20/0 29/0 24/10  A: NS; B: 0.001; C: 0.001
Metabolic syndrome –/+ 20/0 23/6 11/23 A: 0.03; B: < 0.001; C: < 0.001
Total cholesterol [mmol/l] 198 (38) 326 (57) 268 (34) A: < 0.001; B: < 0.001; C: < 0.001
High density lipoprotein [mmol/l] 55 (19) 39 (19) 39 (10) A: 0.027; B: 0.001; C: NS
Low density lipoprotein (mmol/l) 125 (65) 243 (36) 186 (52) A: < 0.001; B: < 0.001; C: <0.001
Apolipoprotein A [mg/dl] 159 (49) 139 (45) 138 (28) A: NS; B: 0.021; C: NS
Apolipoprotein B [mg/dl] 112 (35) 176 (60) 147 (37) A: < 0.001; B: < 0.001; C: 0.002
Lipoprotein (a) [mg/dl] 13 (20) 15 (14) 11 (18) A: NS; B: NS ; C: NS
Glucose [mmol/l] 88 (11) 91 (13) 93 (29) A: NS; B: NS ; C: NS
Insulin [μU/ml] 7 (8) 7 (4) 10 (7) A: NS; B:0.04; C: NS
HOMA-IR 1.4 (2) 1.7 (0.7) 2.4 (2.1) A: NS; B: 0.014; C:0.04
TG0 [mmol/l] 87 (49) 134 (90) 234 (180) A: 0.002; B: < 0.001; C: 0.001
TG2 [mmol/l] 120 (75) 186 (156) 325 (176) A: 0.003; B: < 0.001; C: < 0.001
TG4 [mmol/l] 139 (79) 208 (132) 401 (241) A: 0.002; B: < 0.001; C: < 0.001
TG6 [mmol/l] 124 (96) 230 (156) 359 (217) A: 0.001; B: < 0.001; C: 0.001
TG8 [mmol/l] 97 (77) 187 (122) 317 (170) A: 0.007; B: < 0.001; C: < 0.001
TG AUC [mmol/l/h] 1011 (652) 1503 (1147) 2678 (1415) A: 0.001; B: < 0.001; C: < 0.001
All values are presented as median (IQR) or percentages for categorical variables. TG0 – fasting plasma triglyceride concentration. TG2, TG4, TG6,
TG8 – plasma triglyceride concentration 2, 4, 6, 8 hours after the fat load, respectively. TG AUC – area under the curve for triglycerides 
HOMA-IR – index of homeostasis model of insulin resistance, NS – not statistically significant
A – controls vs. FH, B – controls vs. FCH, C – FH vs. FCH
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Characteristics FH IIA (n = 21) FH IIB (n = 8) FCH IIA (n = 13) FCH IIB (n = 10) FCH IV (n = 11)
Age [years] 37 (12)≠ 37 (12) 49 (15)≠ 45 (8) 48 (9)
BMI [kg/m2] 25 (2)≠ 26 (3) 28 (3)≠ 30 (5) 30 (4)
Waist (cm) 92 (7)≠ 98 (9) 99 (9)≠ 107 (11) 103 (10)
Coronary heart disease  –/+ 18/3 7/1 8/5§ 10/0§ 9/2
Hypertension  –/+ 20/1≠ 5/3 7/6≠ 7/3 7/4
Smokers  –/+ 14/7 2/6 6/7 3/7 2/9
Diabetes mellitus – 21/0≠ 8/0 10/3≠ 8/2 6/5
Metabolic syndrome  –/+ 19/2≠ 4/4 5/8≠ 5/5Ą 1/10Ą
Total cholesterol [mmol/l] 338 (47)≠ 360 (59)† 273 (14)*≠ 277 (25)†Ą 239 (42)*Ą
High density lipoprotein [mmol/l] 47 (15) 40 (9) 43 (11) 37 (8) 38 (6)
Low density lipoprotein [mmol/l] 258 (48)≠ 253 (47)† 204 (18)§*≠ 185 (23)§†Ą 138 (57)*Ą
Apolipoprotein A [mg/dl] 144 (34) 138 (26) 142 (26) 133 (20) 140 (19)
Apolipoprotein B [mg/dl] 176 (54) 189 (48) 152 (28) 160 (16) 155 (45)
Lipoprotein (a) [mg/dl] 23 (24) 18 (10) 21 (16) 10 (6) 28 (41)
Glucose [mg/dl] 90 (8) 92 (7) 105 (38) 120 (42) 122 (68)
Insulin [μU/ml] 7 (4) 8.5 (3) 8 (5) 14 (8) 12 (7)
HOMA-IR 1.7 (0.9) 2.6 (1.8) 1.9 (1.1)§ 4.4 (2.6)§ 4.4 (4.5) 
TG0 [mmol/l] 110 (32) 238 (44) 124 (33)§* 276 (51)§ 333 (125)*
TG2 [mmol/l] 168 (61)≠ 310 (79) 225 (86)§*≠ 413 (111)§ 377 (108)*
TG4 [mmol/l] 203(73) 391(107) 270(103)§* 520 (145)§ 434 (121)*
TG6 [mmol/l] 198 (77)≠ 457 (142) 276 (104)§*≠ 478 (117)§ 442 (129)*
TG8 [mmol/l] 146 (60)≠ 346 (144) 204 (67)§*≠ 373 (61)§ 383 (97)*
TG AUC [mmol/l/h] 1374 428)≠ 2992 (660) 1863 (577)§*≠ 3409 (770)§ 3220 (824)*
All values are presented as mean ±SD or percentages for categorical variables. TG0 – fasting plasma triglyceride concentration, TG2, TG4, TG6,
TG8 – plasma triglyceride concentration 2, 4, 6, 8 hours after the fat load, respectively, TG AUC – area under the curve for triglycerides, HOMA-
IR – index of homeostasis model of insulin resistance, NS – not statistically significant
≠ Significantly different between groups FCH IIA and FH IIA (p ≤ 0.05), † Significantly different between groups FCH IIB and FH IIB (p ≤ 0.05), 
§ Significantly different between groups FCH IIA and FCH IIB (p ≤ 0.05), * Significantly different between groups FCH IIA and FCH IV (p ≤ 0.05), 
Ą Significantly different between groups FCH IIB and FCH IV (p ≤ 0.05)
Table II. Clinical characteristics of different subgroups according to lipoprotein phenotype
investigators; however, the number of patients in
these studies was relatively small [28-29]. In our
study, TG-AUC was 264% higher compared to the
control group, which is lower than that found by
others [28]. In addition, peak TG levels (401 ±241
mg/dl) were seen at 4 h following the fat loading
test and were lower than peak TG levels found by
others [28, 29]. The above findings could be partially
attributed to the different amount of fat load that
was used by other investigators. Based on our
previous studies, we defined an increased TG
response to the fatty meal as any postprandial TG
concentration higher than the highest TG
concentration (220 mg/dl) observed in healthy
subjects [30].
To our knowledge, this is the first study to
compare postprandial lipaemia between FH and
FCH. The FCH group demonstrated higher TG0
levels, abnormal postprandial lipaemia and delayed
TG clearance, compared to FH. Hypercholes  -
terolaemic FCH patients (IIA) showed significantly
higher postprandial TG, in comparison to FH
patients with the same Fredrickson phenotype,
despite the fact that TG0 concentrations were
normal in both groups and did not differ
significantly. There are two possible explanations
for this. Firstly, FCH-IIA patients were older than FH-
IIA (mean age 49[15] vs. 37[12]; p = 0.01). Other
studies have shown that the postprandial TG
response becomes impaired with aging [31].
Secondly, hypertension, DM and central obesity (as
expressed by waist circumference) were more
prevalent in the FCH-IIA group (p = 0.004, p = 0.02
and p = 0.03, respectively). The prevalence of884 Arch Med Sci 6, December / 2010
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metabolic syndrome among FCH-IIA and FH-IIA
patients was 62% and 10% respectively. Our
previous study clearly showed that male patients
with metabolic syndrome demonstrate abnormal
TG clearance following a fat loading test, even when
TG0 levels are within normal limits [20].
Hypertension and DM have also been linked to
abnormal postprandial lipaemia [15, 32].
On the other hand, although the FCH-IIB
subgroup demonstrated higher fasting and
postprandial TG levels, compared to FCH-IV, these
differences never reached statistical significance.
Parameters that can affect postprandial clearance,
such as DM, hypertension, metabolic syndrome and
obesity, did not differ among the two subgroups,
while TG0 levels were comparable. An important
finding of the present study is the fact that
phenotypes FCH-IIB and FCH-IV, which showed
a greater postprandial response, had lower LDL
levels, but higher levels of glucose and insulin
(although the differences were not statistically
significant), with high prevalence of diabetes.
Diabetic FCH patients were compared to non-
diabetic FCH patients and no additional exa  -
cerbation of postprandial lipaemia was revealed
(data not shown). Insulin resistance has been linked
to abnormal postprandial response [20-23, 33]. It is
associated with fasting hypertriglyceridaemia [34],
downregulation of LDLr [35] and overproduction of
VLDL particles [36, 37]. These effects increase
competition between chylomicron and VLDL
remnants for hepatic receptors, thereby impairing
the uptake of CM remnants by this pathway [38].
It is also known that in dyslipidaemias with IIB and
IV phenotypes, where insulin resistance is usually
common, cholesteryl ester transfer protein (CETP)
acts as a mediator for the production of atherogenic
small dense LDL particles [39]. 
Assessing the postprandial response in different
phenotypic expressions of FCH can be of great
clinical importance, in view of the intra-individual
variability of the lipid profile. Phenotypic alterations,
in the same subject, can cause a variable
postprandial TG clearance in different periods of
time, and therefore periodic adjustment of
hypolipidaemic treatment may be required.
Limitations of our study include the small
number of patients in the different subgroups and
the non-age-matched comparisons between the
main groups. 
In summary, FH and FCH subgroups with
hypertriglyceridaemic and mixed phenotypes
demonstrate a significantly abnormal postprandial
TG response. These subgroups of patients should
be identified early and receive appropriate
hypolipidaemic treatment, as they may be at higher
risk of developing early atherosclerosis. This is
especially a challenge in FCH patients who show
intra-individual variability of their lipid profile and
possibly alter their postprandial metabolic status,
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Figure 1. Comparison of TG concentrations at 0, 2, 4, 6, 8 hours between the three different familial combined
hyperlipidaemia (FCH) subgroups, according to Fredrickson lipoprotein phenotype
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within a certain period of time. Fibrates or statins
with a potent effect on TG or combination therapy
with statins plus fibrates or statins plus niacin could
be considered as the appropriate treatment,
according to the fasting phenotype. 
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